Astrin Biosciences Expands Certitude™ Breast with New Leadership in Cancer Detection

Astrin Biosciences Appoints Dr. Tanya Gupta as Medical Director

In a landmark move, Astrin Biosciences has recently appointed Dr. Tanya Gupta as their new Medical Director. This decision coincides with the national expansion of their innovative product, Certitude™ Breast, which represents a significant leap in the detection of breast cancer. Dr. Gupta brings extensive experience and knowledge in breast oncology to the team, enhancing Astrin’s leadership in the cancer diagnostics field.

Dr. Gupta joins Astrin at a critical juncture when the company is scaling its first-of-its-kind, non-invasive blood test aimed at the early detection of breast cancer. This product utilizes cutting-edge deep proteomics technology, which analyzes molecular signals from over 9,000 proteins to identify cancer, particularly in women with dense breast tissue where traditional mammography is less effective.

The recent publication of Astrin's peer-reviewed study titled "Development and Validation of a Machine-Learning Deep Plasma Proteome Classifier for Early Stage Breast Cancer Detection" has underscored the test's high sensitivity and specificity, marking it as a game-changer in oncology.

Jayant Parthasarathy, the CEO of Astrin Biosciences, expressed his enthusiasm for Dr. Gupta's appointment. He emphasized the importance of balancing scientific rigor with clinical empathy, two qualities that Dr. Gupta embodies. As Parthasarathy noted, “Behind every early detection test is a person waiting for answers.” Her role will be paramount in ensuring the seamless integration of Certitude™ Breast into standard clinical practices, which is essential to guiding patients toward timely and life-saving care.

Dr. Tanya Gupta's Background and Contributions

Dr. Gupta boasts a remarkable educational and professional background. She completed her bachelor’s degree and M.D. at the University of California, San Diego, graduating with the highest honors and securing her place in the prestigious Gold Humanism in Medicine Honor Society. Following this, she pursued her internship and residency in Internal Medicine at Stanford University, serving as Chief Resident during her time there. Her fellowship in Hematology and Medical Oncology was also completed at Stanford, consolidating her expertise in the field.

Previously, Dr. Gupta worked at Stanford as a Clinical Assistant Professor and conducted research on numerous breast oncology clinical trials. Her outstanding contributions to the field were recognized in 2020 when she received the American Society of Clinical Oncology’s Bonadonna Breast Cancer Research Grant.

Her commitment to advancing innovative approaches in cancer detection reflects her belief in the potential to significantly improve patient outcomes. Dr. Gupta articulated her vision for Certitude™ as an exciting development in medical technology, stating that it has the potential to revolutionize the ways in which breast cancer is detected, broadening the scope for early diagnosis.

Certitude™ Breast: A New Era in Breast Cancer Detection

Certitude™ Breast is designed for women aged 40 and older, particularly those with dense breast tissue, as well as high-risk patients seeking additional risk stratification. Following standard screening mammography, this blood test serves as a non-imaging alternative that helps guide the need for further imaging tests, thus enhancing the overall screening process.

Astrin Biosciences is dedicated to revolutionizing cancer diagnostics through advanced technologies. Their efforts aim to develop highly sensitive and non-invasive tests that facilitate early cancer detection, with an ultimate goal of ending cancer as we know it.

For those interested in learning more about Certitude™ Breast or exploring Astrin's suite of diagnostic tools, further information can be found on the company’s official website at certitudetest.com and astrinbio.com.

Conclusion

With Dr. Tanya Gupta’s appointment as Medical Director and the national rollout of Certitude™ Breast, Astrin Biosciences is poised to make significant strides in the realm of breast cancer detection and treatment, continuing their mission of transforming oncology through innovative technology.